The Center for Biosimilars® recaps the top news of 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the most-read biosimilars articles for the year of 2018.
Number 5: In July, the FDA released its Biosimilar Action Plan.
Number 4: In September, the State of California sued AbbVie for allegedly using kickbacks and nurse ambassadors to boost adalimumab sales.
Number 3: In June, the FDA approved the first pegfilgrastim biosimilar, Fulphila.
Number 2: In April, the United Kingdom’s National Health Service prepared for the arrival of biosimilar adalimumab.
Number 1: In June, the FDA rejected Amgen’s trastuzumab biosimilar, ABP 980.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.